Clinical inertia, poor drug adherence and low disease awareness are crucial challenges in achieving glycaemic targets, especially in the real-world clinical setting |
Experts from six European countries and Israel reviewed current evidence on the status of insulin initiation in insulin-naïve people with type 2 diabetes, along with considerations in special populations |
Early initiation of a combination therapy, without undue delay of insulin initiation, can be instrumental in achieving and sustaining glycaemic targets as well as attenuating the development of chronic complications |
A less complex treatment regimen that requires fewer adjustments and measurements may facilitate timely achievement of glycaemic targets in routine clinical practice |
Introduction
Methods
Discussion
Right Time for Insulin Initiation
Circumstance | Remark | Therapy | Potential for de-escalation |
---|---|---|---|
Acute glycaemic emergency | |||
Diabetic ketoacidosis Hyperglycaemic hyperosmolar state | i.v. pump, followed by MDI/sc. pump | After treatment | |
Acute glycaemic deterioration | |||
Acute stress (i.e., stroke, sepsis) Surgery Steroid therapy | Severe or symptomatic hyperglycaemia | BI/MDI/sc. pump | After cause is treated |
Chronic hyperglycaemia | |||
Newly diagnosed diabetes | Independent of glycaemia levels (to induce remission) | MDI/sc. pump | After days/weeks |
Severe or symptomatic hyperglycaemia | BI/MDI /sc. pump | After weeks/months | |
On single non-insulin agent | Severe or symptomatic hyperglycaemia | BI/MDI /sc. pump | After days/weeks |
On multiple non-insulin agents including injectables | Glycaemia above personal target | BI | Possible on long term |
Severe or symptomatic hyperglycaemia | BI/MDI /sc. pump | After weeks/months | |
On combination of BI and non-insulin agents including injectables | Glycaemia above personal target | MDI /sc. pump | Possible on long term |
Newly Diagnosed T2D
Individuals on Single OAD with Uncontrolled Glycaemic Target
Indications for Insulin Treatment in T2D
Absolute Indications for Insulin Treatment in T2D
Glycaemic Levels—Main Criteria for Insulin Initiation
Additional, Non-mandatory Conditions for Initiating Insulin
Recommended Type of Insulin and Regimen
Basal-Supported Non-insulin Therapy
Meal-Time Insulin (MTI)
Insulin Treatment Choice for Older Adults with T2D
Insulin regimen | Pros | Cons |
---|---|---|
NPH | Established efficacy Inexpensive | Requires resuspension High risk of hypoglycaemia and weight gain Variable glucose-lowering effect per injection |
First-generation BI analogues (Gla-100, IDet) | Lower risk of hypoglycaemia than NPH insulin Once-daily injection possible Less variable absorption and longer duration of action | Requirement of injection at same time each day may be troublesome |
Second-generation BI analogues (Gla-300, IDeg) | Less GV and prolonged duration of action Increased dosing flexibility Lower hypoglycaemia risk compared to Gla-100 | More expensive than other BI (possibly offset by reduced need for nurse visits ± and longer-lasting pens) |
Insulin Treatment Choice for PwT2D and CKD
Insulin Treatment Choice in PwT2D and CVD
Insulin Treatment Choice in PwT2D and High Risk of Hypoglycaemia
Ways to Increase Adherence to Insulin Treatment
Issue with insulin treatment | Solutions to improve adherence |
---|---|
Frequency of injections (daily/multiple) | BI analogues with once-daily administration compared with NPH or IDet Preference of BOT or FRC of BI + GLP-1RA to MDI regimen |
Hypoglycaemia risk | Second-generation analogues (Gla-300 or IDeg) with lower risk of hypoglycaemia vs NPH and first- generation analogues (Gla-100 or IDet) |
Weight gain | BI insulin analogues vs NPH Preference of BI to MDI Preference of FRC of BI + GLP-1RA to MDI after BI failure or as de-escalation of current MDI regimen |
Impact on lifestyle | Second-generation analogues (Gla-300 or IDeg) with once-daily administration and flexibility in daily injection time compared with NPH and first-generation analogues (Gla-100 or IDet) Preference of BOT or FRC of BI + GLP-1RA to MDI regimen |
Difficulties with devices | Prefer insulin pre-filled pens to syringe/vials or reusable pens |
Complicated insulin dose titration | Select simple titration schemas (+ 1 U/day) Use of CGM for timely insulin dose change |
Fear of insulin use and fear of needles/pain | Regular and quality interactions between the HCPs and individuals and caregivers; Patient education |